GlassScriptPhysician profile
Thomas W Butler
NPI 1942206636
$407.34
in general payments reported to CMS, 2019-2025
10 companies · $46.49 in 2025
The $46.49 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $32.31 · 2022: $64.32 · 2023: $41.00 · 2024: $88.18 · 2025: $46.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.30 | 2022-2024 | Mounjaro, Zepbound, Humulin |
| Corcept Therapeutics | $73.67 | 2019-2022 | |
| Amgen INC. | $46.71 | 2019 | |
| Eisai INC. | $34.88 | 2019 | |
| Shire North American Group INC | $23.89 | 2019 | |
| Tandem Diabetes Care, INC. | $23.89 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $23.81 | 2022 | |
| Novo Nordisk INC | $22.74 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $22.60 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.